MRKR Insider Trading

Insider Ownership Percentage: 14.50%
Insider Buying (Last 12 Months): $1,809,072.00
Insider Selling (Last 12 Months): $0.00

Marker Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Marker Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Marker Therapeutics Share Price & Price History

Current Price: $1.18
Price Change: Price Decrease of -0.22 (-15.71%)
As of 03/13/2025 05:00 PM ET

This chart shows the closing price history over time for MRKR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$1.40Closing price on 03/12/25:

Marker Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Marker Therapeutics (NASDAQ:MRKR)

22.39% of Marker Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MRKR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.54Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal InflowsTotal Outflows
Marker Therapeutics logo
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Read More on Marker Therapeutics

Today's Range

Now: $1.18
Low: $1.13
High: $1.39

50 Day Range

MA: $2.01
Low: $1.38
High: $3.29

52 Week Range

Now: $1.18
Low: $1.13
High: $5.99

Volume

157,849 shs

Average Volume

149,177 shs

Market Capitalization

$12.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Who are the company insiders with the largest holdings of Marker Therapeutics?

Marker Therapeutics' top insider shareholders include:
  1. Enterprise Associates 16 New (Major Shareholder)
  2. Steve Elms (Director)
  3. Norman David Eansor (Director)
Learn More about top insider investors at Marker Therapeutics.

Who are the major institutional investors of Marker Therapeutics?

Marker Therapeutics' top institutional investors include:
  1. NEA Management Company LLC — 15.18%
  2. Alyeska Investment Group L.P. — 8.55%
  3. Blue Owl Capital Holdings LP — 5.18%
  4. Aisling Capital Management LP — 3.04%
  5. LPL Financial LLC — 0.74%
  6. Northern Trust Corp — 0.51%
Learn More about top institutional investors of Marker Therapeutics stock.

Which major investors are buying Marker Therapeutics stock?

Within the last quarter, MRKR stock was acquired by institutional investors including:
  1. Alyeska Investment Group L.P.
  2. NEA Management Company LLC
  3. Blue Owl Capital Holdings LP
  4. LPL Financial LLC
  5. Northern Trust Corp
  6. Millennium Management LLC
  7. Aisling Capital Management LP
In the last year, these company insiders have bought Marker Therapeutics stock:
  1. Enterprise Associates 16 New (Major Shareholder)
  2. Steve Elms (Director)
  3. Norman David Eansor (Director)
Learn More investors buying Marker Therapeutics stock.